“…The rapid review reported concerns about the assumptions made regarding non-participation in genomic studies. Concerns included those related to privacy (Buseh et al, 2013; Abadie and Heaney, 2015 ; Simon et al, 2017 ; Garrison et al, 2019 ; Lee et al, 2019 ; Reddy et al, 2020 ; De Ver Dye et al, 2021 ; Hendricks-Sturrup and Johnson-Glover, 2021 ), stigmatisation (Marsh et al, 2013 ; Abadie and Heaney, 2015 ; Faure et al, 2019 ), commodification of data leading to dispossession (Abadie and Heaney, 2015 ) and re-use of data beyond the scope of the original research 9 (de Vries et al, 2014 ); for example, by commercialisation of the research and unjust corporate profiteering (Lee et al, 2019 ). It was noted that whilst such concerns may be common amongst other groups, they might be heightened for those from underserved groups due to experiences of stigmatisation, discrimination and prejudicial judgement (Abadie and Heaney, 2015 ), 10 particularly in cases of disease-related stigma (Ali-Khan and Daar, 2010 ; Faure et al, 2019 ).…”